| Project/Area Number |
15K15185
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
異島 優 徳島大学, 大学院医歯薬学研究部(薬学系), 准教授 (00457590)
渡邊 博志 熊本大学, 薬学部, 准教授 (70398220)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | ドラッグデリバリーシステム / ドラックデリバリー / ドラッグデリバリー |
|---|
| Outline of Final Research Achievements |
We have been constructed the albumin DDS platform that is albe to create albumin dervaties with active targeting potency and multiple functions. The purpose of the present study is to attempt a developement of novel immunotherapy which convert M2 type tumor associated macrophage to its M1 type. To achive this strategy, it must be nessesary to construct a novel DDS system to TAM. Here, we originally develop a TAM tardeting carrier based on recombinant mannosylated albumin with PEGlation (PEGlated Man-HSA). Actually, this carrier preferentially distributed to tumor tissues and simultaneously reduced the distribution to liver. Using albumin fusion technology, M1-inducers were attached to PEGlated Man-HSA, and it retained M1 inducing ability. Administration of M1-PEGlated Man-HSA caused the alternation of TAM phenotype from M2 type to M1 like type, and hence, suppresed the tumor growth significantly. Thus, M1-PEGlated Man-HSA has a potential as a novel immunotherapy against cancer.
|
